RT Journal Article
SR Electronic
T1 Epidemiology and precision of SARS-CoV-2 detection following lockdown and relaxation measures
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.09.22.20198697
DO 10.1101/2020.09.22.20198697
A1 Leuzinger, Karoline
A1 Gosert, Rainer
A1 Søgaard, Kirstine K.
A1 Naegele, Klaudia
A1 Bielicki, Julia
A1 Roloff, Tim
A1 Bingisser, Roland
A1 Nickel, Christian H.
A1 Khanna, Nina
A1 Sutter, Sarah Tschudin
A1 Widmer, Andreas F.
A1 Rentsch, Katharina
A1 Pargger, Hans
A1 Siegemund, Martin
A1 Stolz, Daiana
A1 Tamm, Michael
A1 Bassetti, Stefano
A1 Osthoff, Michael
A1 Battegay, Manuel
A1 Egli, Adrian
A1 Hirsch, Hans H.
YR 2020
UL http://medrxiv.org/content/early/2020/09/23/2020.09.22.20198697.abstract
AB Introduction SARS-CoV-2-detection is critical for clinical and epidemiological assessment of the ongoing CoVID-19 pandemic.Aim To cross-validate manual and automated high-throughput (Roche-cobas®6800-Target1/Target2) testing for SARS-CoV-2-RNA, to describe detection rates following lockdown and relaxation, and to evaluate SARS-CoV-2-loads in different specimens.Method The validation cohort prospectively compared Basel-S-gene, Roche-E-gene, and Roche-cobas®6800-Target1/Target2 in 1344 naso-oropharyngeal swabs (NOPS) taken in calendar week 13 using Basel-ORF8-gene-assay for confirmation. Follow-up-cohort-1 and -2 comprised 12363 and 10207 NOPS taken over 10 weeks until calendar week 24 and 34, respectively. SARS-CoV-2-loads were compared in follow-up NOPS, lower respiratory fluids, and plasma.Results Concordant results were obtained in 1308 cases (97%) including 97 (9%) SARS-CoV-2-positives showing high quantitative correlations (Spearman r>0.95; p<0.001) for all assays. Discordant samples (N=36) had significantly lower SARS-CoV-2-loads (p<0.001). Following lockdown, weekly detection rates declined to <1% reducing single-test positive predictive values from 99.3% to 85.1%. Following relaxation, rates flared up to 4% with similarly high SARS-CoV-2-loads, but patients were significantly younger than during lockdown (34 vs 52 years, p<0.001). SARS-CoV-2-loads in follow-up NOPS declined by 3log10 copies/mL within 10 days post-diagnosis (p<0.001). SARS-CoV-2-loads in NOPS correlated weakly with those in time-matched lower respiratory fluids and plasma, but remained detectable in 14 and 7 cases of NOPS with undetectable SARS-CoV-2, respectively.Conclusion Evaluated manual and automated assays are highly concordant and correlate quantitatively. Following successful lockdown, declining positive predictive values require dual-target-assays for clinical and epidemiologic assessment. Confirmatory and quantitative follow-up testing should be considered within <5 days, using lower respiratory fluids in symptomatic patients with SARS-CoV-2-negative NOPS.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNot a clinical trialFunding StatementThis study was supported by the Clinical Virology Division, Laboratory Medicine, University Hospital Basel, Basel, Switzerland, and appointment grant to HHH, Department Biomedicine, University of Basel, Basel, Switzerland.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was conducted according to good laboratory practice and in accordance with the Declaration of Helsinki and national and institutional standards for laboratory quality control and was approved by the Ethical Committee of North-western and Central Switzerland (EKNZ 2020-00769).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data are available at a secure server accessed only by the research team, but restrictions apply to guarantee pseudonymized patient identity.